Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Accepts healthy volunteers

Safety and Efficacy Study of Herpes Simplex Virus Type 2 (HSV-2) Therapeutic DNA Vaccine

ClinicalTrials.gov ID: NCT02837575

Public ClinicalTrials.gov record NCT02837575. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 23, 2026, 1:09 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial to Evaluate the Safety and Efficacy of Herpes Simplex Virus, Type 2 (HSV-2) Therapeutic DNA Vaccine in Adults With Symptomatic Genital HSV-2 Infection

Study identification

NCT ID
NCT02837575
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Vical
Industry
Enrollment
261 participants

Conditions and interventions

Interventions

  • VCL-HB01 Biological
  • Phosphate-buffered saline Other

Biological · Other

Eligibility (public fields only)

Age range
18 Years to 50 Years
Sex
All
Healthy volunteers
Accepts healthy volunteers

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Aug 31, 2016
Primary completion
Mar 31, 2018
Completion
Nov 30, 2018
Last update posted
Feb 26, 2019

2016 – 2018

United States locations

U.S. sites
15
U.S. states
13
U.S. cities
15
Facility City State ZIP Site status
Alabama Vaccine Research Clinic at University of Alabama at Birmingham Birmingham Alabama 35294-2050
Medical Center for Clinical Research San Diego California 92108
QPS Broward Research Hollywood Florida 33024
QPS Miami Research Associates South Miami Florida 33143
Comprehensive Clinical Trials, LLC West Palm Beach Florida 33409
University of Illinois Chicago Illinois 60612
Indiana University Infectious Disease Research Indianapolis Indiana 46202
Heartland Research Associates, LLC Wichita Kansas 67207
Central Kentucky Research Associates, Inc. Lexington Kentucky 40509
The Center for Pharmaceutical Research Kansas City Missouri 64114
Rochester Clinical Research, Inc. Rochester New York 14609
University of North Carolina (UNC) Institute of Global Health and Infectious Diseases Chapel Hill North Carolina 27599
Clinical Research Associates, Inc. Nashville Tennessee 37203
University of Utah School of Medicine - Division of Infectious Diseases Salt Lake City Utah 84132
University of Washington Seattle Washington 98104

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02837575, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Feb 26, 2019 · Synced Jul 23, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02837575 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →